Defining the Target, Dose, & Indication for Complete Immune Reset Beyond CD20
- Distinguishing diseases driven by CD20+ B-Cells from those driven by plasma cells to inform the choice of alternative targets such as BCMA and CD38
- Harnessing available clinical data to inform target selection and match T-cell engager targets to the correct autoimmune indication
- Exploring the dosing challenges for high-efficacy T-cell engagers and determining whether intermittent high doses or continuous lower doses are optimal to balance efficacy and safety